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Antidepressants have a peculiar place in the public mind. Almost every
family in the UK will have someone taking these drugs; yet, the media are
often very hostile to them with disparaging terms such as ‘happy pills’ used to
cast aspersions on their efficacy and utility [1]. Moreover, claims that they may
cause suicidal ideation particularly in young people have led to warning labels
in the USA. Yet, despite the repeated media criticism, the use of antidepres-
sants continues to be widespread. So, what are the reasons for this?
The first is that they are effective and the disorders they are used to treat are
very common. Depression is predicted to be largest cause of disability in the
world by 2020 [2] and is now exceeding that of cardiovascular disease in
many western countries (making it number one there already). Moreover,
several of the anxiety disorders are also in the top ten causes of disability, and
these also respond very well to antidepressant treatment.
In their primary target of depression, the antidepressants are effective
treatments of the acute phase with a number needed to treat (NNT) of
about 6, which compares favourably with treatments in other branches
of medicine. However, when used in the long term to prevent recurrence of
depression, they become even more effective with an NNT of 3 [3]. This
makes them one of the most effective of any medicine: for comparison the
NNT of statins to prevent the recurrence of a myocardial infarction is
about 20.
Similar efficacy is seen in their secondary indications of the treatment of
anxiety disorders. Moreover, the desire of many countries to reduce the
prescribing of benzodiazepines has led to a switch to the new antidepress-
ants, particularly the selective serotonin reuptake inhibitors (SSRIs) that
have greater efficacy and are much freer from problems such as abuse and
withdrawal [4]. Although the SSRIs take several weeks to work and can even
worsen anxiety at the start of treatment after a few weeks, they become very
effective anxiolytic treatments with efficacy exceeding that of the benzo-
diazepines. The SSRIs also have uses in other indications such as pain, some
sleep disorders and some sexual problems (particularly SSRIs for premature
ejaculation).
There are other factors underlying this increase in use. The most important
one is that the newer antidepressants are extremely safe drugs. Before their
invention, the most commonly used antidepressants were those of tricyclic
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110 Current Commentsstructure such as amitriptyline and duselepin. However,
these are very toxic in overdose due to their combination
of noradrenaline reuptake blocking properties and
marked anticholinergic actions on the heart. At the peak
of their use, they were the most common cause of drug
overdose death in the UK, and still today kill hundreds of
people a year [5]. Patients with depression are at very high
risk of suicide, and before the onset of the SSRIs, many
used their antidepressants to kill themselves.
The newer generation of antidepressants is exemplified
by the SSRIs, but venlafaxine, duloxetine, mirtazapine
and agomelatine are also orders of magnitude safer than
the tricyclics in overdose and much preferred by psychia-
trists for this reason. In practice, it is extremely difficult to
kill oneself with an overdose of these medicines alone and
the cases of suicidal ideation have been minimal and have
not led to actual suicides. The very enhanced safety and
tolerability profile of these newer antidepressant drugs
has led to a greater use of them in the depressed popu-
lation because patients’ compliance with medication is
enhanced and doctors are more comfortable prescribing
them. This in turn has resulted in a reduction in suicide
rate in many countries where their use has become wide-
spread [6].
Despite this, depression is still under-treated with up to
half of all patients not being appropriately diagnosed or
treated [7]. Efforts to improve this situation are underway,Current Opinion in Pharmacology 2012, 12:109–110 and are more necessary today than was the case a few
years ago because depression and suicide rates in Europe
are on the rise as a result of the economic downturn [8]. It
therefore appears to be the case that the use of anti-
depressants is large and growing but still inadequate to
meet the needs of the population.
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